Lakefront Biotherapeutics (LKFT) Short-term Investments (2014 - 2023)

Lakefront Biotherapeutics (LKFT) has reported Short-term Investments for 13 consecutive years, with $3.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 1.74% year-over-year to $3.4 billion; the TTM figure through Mar 2026 stood at $3.4 billion (up 1.74% YoY), while the FY2025 annual figure was $3.5 billion, down 1.57% from the prior year.
• Short-term Investments grew to $3.4 billion in Q1 2026 per LKFT's latest filing, from $3.4 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $4.1 billion in Q1 2023 and bottomed at -$2.5 billion in Q3 2022.
• Historically, Short-term Investments has averaged $2.8 billion across 5 years, with a median of $3.4 billion in 2025.
• Annual changes were most pronounced in 2022 — Short-term Investments plunged 53.33% — and 2025, when it jumped 14939.28%.
• Lakefront Biotherapeutics' Short-term Investments stood at $1.3 billion in 2022, then soared by 187.02% to $3.8 billion in 2023, then retreated by 13.79% to $3.3 billion in 2024, then advanced by 3.82% to $3.4 billion in 2025, then grew by 0.76% to $3.4 billion in 2026.
• Business Quant data shows LKFT's Short-term Investments at $3.4 billion in Q1 2026, $3.4 billion in Q4 2025, and $3.7 billion in Q3 2025.